
Health Canada’s Nod to Pfizer’s Gene Therapy
Pfizer starts 2024 with the approval of its gene therapy, Beqvez (fidanacogene elaparvovec), by Health Canada. This approval is for adults aged 18 and older with a moderately-severe to severe form of hemophilia B, who do not have neutralizing antibodies against AAV serotype Rh74.
Beqvez: How It Works
introduces a high-activity human FIX gene to enable patients to produce the FIX clotting protein endogenously, a departure from the regular intravenous infusions. The Phase III BENEGENE-2 study, crucial for this approval, showed that Beqvez effectively reduced annualized bleeding rates compared to standard FIX prophylaxis.
Hemophilia B: A Brief Overview
Hemophilia B is a genetic disorder characterized by insufficient FIX clotting protein, leading to prolonged bleeding, especially into joints and muscles. It affected over 38,000 people globally in 2021, with more than 700 cases in Canada. The disorder is typically X-linked recessive and primarily affects males.
FDA Review and Pfizer’s Strategic Shift
While Health Canada has granted approval, Pfizer awaits a decision from the US Food and Drug Administration (FDA), expected by mid-2024. Concurrently, Pfizer has announced a shift in its strategy, moving away from developing viral vector-based gene therapies.
Financial Repercussions and Strategy Adjustment
Facing reduced sales from its COVID-19 vaccine and antiviral products, Pfizer is implementing a $4 billion cost-cutting initiative, heavily affecting research and development. Part of its strategic realignment involves a potential $1 billion deal transferring some of its assets and programs to Alexion, a division of AstraZeneca.
Market Dynamics: Beqvez and Hemgenix
With the approval of Beqvez, Pfizer enters a market that includes CSL Behring’s Hemgenix (etranacogene dezaparvovec), another gene therapy for hemophilia B. Hemgenix, priced at $3.5 million, was approved by the FDA in November 2022 and Health Canada in October 2023. The price of Beqvez is yet to be announced.
Conclusion: The Entry of Beqvez into Genetic Medicine
The approval of Beqvez by Health Canada introduces a new gene therapy option for hemophilia B. As Pfizer adjusts its business strategy, the healthcare community awaits the potential impact of Beqvez on genetic medicine treatments.
Related News
A Global Alliance to Save Lives: How Two Parents and PackGene Are Redefining What’s Possible in Gene Therapy with Help from Weill Cornell Medicine
HOUSTON, TX – Two Australian parents, faced with the unimaginable prospect of losing their 14-month-old daughter to the ultra-rare neurological disease Hereditary Spastic Paraplegia Type 56 (SPG56), sold their home and everything they owned to save their daughter....
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Related Services

Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE

AAV cGMP Manufacturing
READ MORE

AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE